UPDATE: Exact Sciences Revenues Up More Than Twofold on Cologuard Sales | GenomeWeb

This article has been updated to include comments from the company's call with analysts after the earnings release.

NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Tuesday that its first quarter revenues rose more than twofold, thanks in large part to a 260 percent increase in the number of Cologuard colorectal cancer screening tests completed during the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.